PNS and Medication Reduction: The Clinical Evidence

Chronic joint pain is frequently managed, at least in part, with pharmacological treatments — NSAIDs, acetaminophen, topical agents, and in more severe cases, opioid analgesics. For many patients, long-term medication use carries significant burdens: gastrointestinal effects from NSAIDs, kidney and liver considerations with extended use, and the well-documented risks of opioid dependence, tolerance, and dose escalation.

Medication management provides relief for many patients, but it is rarely a complete or permanent solution for chronic joint pain. It addresses symptoms without addressing the underlying pain mechanism, and its effectiveness often plateaus or diminishes over time as tolerance develops.

The COMFORT randomized trial of implantable PNS, summarized at 24 months in Practical Neurology (2026), reported large pain reductions and significant improvements in disability (ODI), depression (BDI), and quality of life (EQ-5D-5L) in the followed cohort. Those outcomes can translate into less need for rescue medication for some patients, but that summary does not provide a headline statistic on percentage of patients who reduced opioids or other analgesics — so we do not quote one here. Sources: https://practicalneurology.com/news/implantable-peripheral-nerve-stimulation-shows-durable-pain-relief-at-24-months/2485516/ and https://doi.org/10.29011/2576-957X.100079

In routine care, many people still aim to lower their medication burden when nerve-targeted therapy works. That goal should be explicit in visits with your prescribing physician, with any taper supervised medically — never based on website copy alone.

PNS and analgesic medication are not mutually exclusive. Some patients use both during treatment, and the two approaches work through entirely different mechanisms. PNS modulates the nerve signaling pathway; medications work through systemic pharmacological pathways. In appropriately selected patients, both can be part of an integrated pain management strategy.

The clinical goal, however, is not to add another layer of treatment indefinitely — it's to achieve adequate pain control with the least pharmacological burden. When pain and function improve (as in the COMFORT outcomes summarized above), some patients work with their clinicians to reduce rescue or baseline medications — but that is a care-plan decision, not something this site can promise from a single trial summary.

In the context of ongoing national attention to opioid prescribing and dependence, many patients hope neuromodulation will make opioids easier to taper. That may be true in individual cases when pain is better controlled, but the COMFORT 24-month news summary cited above does not report a dedicated opioid-reduction endpoint — so we do not cite a percentage here.

Patients who have been on long-term opioid therapy and who achieve meaningful pain control through PNS may, in coordination with their prescribing physician, be able to reduce or eliminate opioid use over time. That is never a guaranteed outcome, and tapering must always be supervised medically.

Evaluating PNS outcomes only through the lens of pain scale reduction misses part of what the treatment accomplishes. A complete assessment includes changes in medication requirements, improvements in functional ability, sleep quality, and patient-reported quality of life. When these outcomes are considered together, the clinical benefit of PNS in appropriate patients extends significantly beyond the number on a pain scale.

Patients who are candidates for PNS — particularly those with long-standing chronic joint pain currently managed with regular analgesic or opioid use — should discuss medication reduction as an explicit treatment goal with their physician. Setting expectations around this outcome is part of a thorough pre-procedure evaluation.

Not every PNS patient will achieve medication reduction, and it is not appropriate to frame this as an expected outcome for all patients. Response to PNS is individual, and medication reduction — when it occurs — typically happens gradually over months, not immediately following the procedure.

Patients on long-term opioid therapy should not attempt to reduce their medication independently based on early PNS results. Any changes to a medication regimen should be managed in close coordination with the prescribing physician. The goal is safe, gradual reduction guided by clinical assessment — not rapid discontinuation.